SCHEDULE: Millennium Management Discloses Immix Biopharma Stake

Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have jointly filed a Schedule 13G, disclosing beneficial ownership of 3.3% of Immix Biopharma, Inc. common stock as of March 31, 2026.

Summary

• Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have entered into a joint filing agreement to report their beneficial ownership of Immix Biopharma, Inc. common stock.
• As of March 31, 2026, the reporting persons collectively beneficially own 1,750,200 shares of Immix Biopharma, Inc. common stock.
• This ownership represents 3.3% of the total class of securities.
• The filing is an amendment to a Schedule 13G, indicating a change in reporting status or ownership threshold.
• The reporting persons state that the securities are not held for the purpose of influencing the control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It's a standard disclosure of ownership by a large investment firm, indicating interest but not necessarily a strong positive or negative signal about the company's immediate performance.

Positives

• The filing confirms a significant institutional investor's stake in Immix Biopharma, Inc., which can be viewed positively by the market.
• The reporting persons have a shared voting and dispositive power over 1,750,200 shares, indicating a coordinated investment strategy.

Negatives

• The filing does not contain any negative financial information or operational challenges for Immix Biopharma, Inc. as it is a disclosure of ownership.

Risks

• The filing does not explicitly mention any risks related to Immix Biopharma, Inc.'s operations or the investment itself.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding Immix Biopharma, Inc.'s future performance. It solely pertains to the disclosure of beneficial ownership.

Management Comments

• The securities disclosed herein as potentially beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Mr. Englander are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC (the managing member of Millennium Management LLC) and Mr. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC).
• The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities.
• I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

Industry Context

StockSavvy.ai notes that significant filings by large investment management firms like Millennium Management often signal conviction in a company's prospects or a strategic shift in their portfolio. For Immix Biopharma, this disclosure indicates a notable institutional interest.

Stakeholder Impact

• Shareholders may view the increased institutional interest positively, potentially leading to increased demand for the stock.
• The company's management may see this as validation of their strategy, though the filing explicitly states the shares are not held to influence control.

Next Steps

• Monitor future filings from Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander for any changes in their beneficial ownership of Immix Biopharma, Inc. stock.
• Observe Immix Biopharma, Inc.'s strategic developments and financial performance, which may be influenced by institutional investor interest.

Key Dates

Keywords

Schedule 13G, Beneficial Ownership, Immix Biopharma, Millennium Management, SEC Filing, Common Stock, Investment Disclosure